189 related articles for article (PubMed ID: 31902818)
21. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
[TBL] [Abstract][Full Text] [Related]
22. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Wang M; Schuster SJ; Phillips T; Lossos IS; Goy A; Rule S; Hamadani M; Ghosh N; Reeder CB; Barnett E; Bravo MC; Martin P
J Hematol Oncol; 2017 Nov; 10(1):171. PubMed ID: 29096668
[TBL] [Abstract][Full Text] [Related]
23. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
24. A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior.
Kurita D; Takeuchi K; Kobayashi S; Hojo A; Uchino Y; Sakagami M; Ohtake S; Takahashi H; Miura K; Iriyama N; Sugitani M; Miyoshi H; Hatta Y; Ohshima K; Takei M
Virchows Arch; 2016 Oct; 469(4):471-6. PubMed ID: 27457074
[TBL] [Abstract][Full Text] [Related]
25. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
Epperla N; Hamadani M; Cashen AF; Ahn KW; Oak E; Kanate AS; Calzada O; Cohen JB; Farmer L; Ghosh N; Tallarico M; Nabhan C; Costa LJ; Kenkre VP; Hari PN; Fenske TS
Hematol Oncol; 2017 Dec; 35(4):528-535. PubMed ID: 28066928
[TBL] [Abstract][Full Text] [Related]
26. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
27. Stem cell transplant for mantle cell lymphoma in Taiwan.
Wang YH; Hsieh CY; Hsiao LT; Lin TL; Liu YC; Yao M; Tan TD; Ko BS
Sci Rep; 2022 Apr; 12(1):5662. PubMed ID: 35383213
[TBL] [Abstract][Full Text] [Related]
28. Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement.
Takahashi M; Sumitani R; Hori T; Murai J; Kawata S; Oura M; Sogabe K; Harada T; Fujii S; Miki H; Kagawa K; Abe M; Nakamura S
J Med Invest; 2021; 68(1.2):196-201. PubMed ID: 33994471
[TBL] [Abstract][Full Text] [Related]
29. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L
Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073
[TBL] [Abstract][Full Text] [Related]
30. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
31. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.
Graf SA; Stevenson PA; Holmberg LA; Till BG; Press OW; Chauncey TR; Smith SD; Philip M; Orozco JJ; Shustov AR; Green DJ; Libby EN; Bensinger WI; Pagel JM; Maloney DG; Zhou Y; Cassaday RD; Gopal AK
Ann Oncol; 2015 Nov; 26(11):2323-8. PubMed ID: 26347113
[TBL] [Abstract][Full Text] [Related]
32. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
Lefrère F; Delmer A; Suzan F; Levy V; Belanger C; Djabarri M; Arnulf B; Damaj G; Maillard N; Ribrag V; Janvier M; Sebban C; Casasnovas RO; Bouabdallah R; Dreyfus F; Verkarre V; Delabesse E; Valensi F; McIntyre E; Brousse N; Varet B; Hermine O
Leukemia; 2002 Apr; 16(4):587-93. PubMed ID: 11960337
[TBL] [Abstract][Full Text] [Related]
33. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
[TBL] [Abstract][Full Text] [Related]
34. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.
Bernard S; Goldwirt L; Amorim S; Brice P; Brière J; de Kerviler E; Mourah S; Sauvageon H; Thieblemont C
Blood; 2015 Oct; 126(14):1695-8. PubMed ID: 26239089
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
Decaudin D; Brousse N; Brice P; Haioun C; Bourhis JH; Morel P; Van Hoof A; Souleau B; Quesnel B; Gisselbrecht C
Bone Marrow Transplant; 2000 Feb; 25(3):251-6. PubMed ID: 10673695
[TBL] [Abstract][Full Text] [Related]
36. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
37. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.
Mangel J; Leitch HA; Connors JM; Buckstein R; Imrie K; Spaner D; Crump M; Pennell N; Boudreau A; Berinstein NL
Ann Oncol; 2004 Feb; 15(2):283-90. PubMed ID: 14760123
[TBL] [Abstract][Full Text] [Related]
38. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
39. Autotransplantation for mantle cell lymphoma.
Vose JM
Cancer J; 2012; 18(5):427-31. PubMed ID: 23006947
[TBL] [Abstract][Full Text] [Related]
40. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
Dreger P; Michallet M; Bosman P; Dietrich S; Sobh M; Boumendil A; Nagler A; Scheid C; Cornelissen J; Niederwieser D; Müller L; Vandenberghe E; Scortechini I; Schoemans H; Andersen NS; Finke J; Russo D; Ljungman P; Passweg J; van Gelder M; Durakovic N; Labussiere-Wallet H; Berg T; Wulf G; Bethge W; Bunjes D; Stilgenbauer S; Canepari ME; Schaap M; Fox CP; Kröger N; Montoto S; Schetelig J
Bone Marrow Transplant; 2019 Jan; 54(1):44-52. PubMed ID: 29728701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]